The Novo Nordisk Foundation committed 5.5 billion Danish kroner (about $857 million) to the BioInnovation Institute to expand its life science and deep‑tech commercialization work from 2026 through 2035. The funding will scale the institute’s incubator operations, increase company formation and support translational programs aimed at turning academic discoveries into startups across Denmark and potentially other parts of Europe. The foundation—Novo Nordisk’s largest shareholder—says the cash will help close Europe’s commercialization gap by providing capital, infrastructure and advising to academics and founders. Industry observers at JP Morgan flagged the move as a major, long‑term commitment to regional innovation capacity and a potential pipeline source for partnerships and licensing.